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SUMMARY – Diabetes is a chronic disease that requires continual medical care and patient 
self-management education in order to prevent acute complications and to reduce the risk of long-
term complications. Diabetes is the leading known cause of neuropathy in developed countries, and 
neuropathy is the most common complication and the leading source of morbidity and mortality 
in diabetes patients. Diabetic polyneuropathy is primarily symmetric sensory neuropathy, initially 
affecting distal lower extremities. Patients have evidence of nerve damage at the time their diabe-
tes is diagnosed in 10%-18% of cases, suggesting that even early impairment of glucose handling, 
classified as prediabetes, is associated with neuropathy. It is important to appreciate that there are 
other causes of neuropathy; these should be considered if there is any aspect of the history or clinical 
presentation suggesting features atypical of diabetic neuropathy. Diagnosis of diabetic neuropathy 
should be established according to clinical manifestations of the disease, laboratory findings (altered 
glucose metabolism) and results of electrophysiological examinations. Treatment of painful diabetic 
polyneuropathy rests on a two-pronged approach: modification of the underlying disease and con-
trol of pain symptoms. The goals of painful diabetic polyneuropathy pharmacotherapy should be 
reduction of pain for maximum relief commensurate with acceptable side effects and restoration/
improvement in functional measures and quality of life.
Key words: Diabetic neuropathy – therapy; Pain – therapy; Pain – analysis; Guideline
Correspondence to: Assist. Prof. Vanja Bašić-Kes, MD, PhD, Uni-
versity Department of Neurology, Sestre milosrdnice University 
Hospital Center, Vinogradska c. 29, HR-10000 Zagreb, Croatia
E-mail: vanjakes@net.hr
Received July 8, 2011, accepted September 5, 2011
Introduction
Diabetes is a chronic disease that requires con-
tinual medical care and patient self management edu-
cation in order to prevent acute complications and to 
reduce the risk of long-term complications. According 
to the last diagnostic and classification criteria, the 
classification of diabetes includes: 
1) prediabetes: 
•  impaired fasting glycemia 
•  impaired glucose tolerance
2) diabetes mellitus type 1
3) diabetes mellitus type 2
4) diabetes due to other causes: genetic β-cell defects, 
diseases of exocrine pancreas (cystic fibrosis), drug 
or chemical-induced
5) gestational diabetes
Diagnosis of diabetes should be established ac-
cording to clinical signs of diabetes and blood tests 
(fasting plasma glucose, glycosylated hemoglobin and 
oral glucose tolerance test)1. Diabetes is the leading 
known cause of neuropathy in developed countries, 
and neuropathy is the most common complication 
and the leading source of morbidity and mortality 
in diabetes patients. The prevalence of neuropathy in 
diabetes patients has been estimated to approximately 
20%. Diabetic neuropathy is implicated in 50%-75% 
of nontraumatic amputations. These conditions are 
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the consequence of diabetic microvascular injury in-
volving small blood vessels that supply nerves (vasa 
nervorum). There are many forms of diabetic neuropa-
thy including symmetric polyneuropathy, autonomic 
neuropathy, radiculopathies, mononeuropathies, and 
mononeuropathy multiplex1-3.
Pathophysiology
Generally, vascular complications of diabetes can 
be divided into microvascular (diabetic nephropathy, 
neuropathy and retinopathy) and macrovascular (cor-
onary disease, cerebrovascular disease and peripheral 
artery disease) complications. Risk factors for diabetic 
neuropathy have not yet been ascertained, but may in-
clude advanced age, duration of diabetes, lipotoxicity 
and glucotoxicity, genetic susceptibility, inflamma-
tion, and oxidative stress1.
The central pathomorphological mechanism of these 
complications is atherosclerosis, which leads to narrow-
ing of arterial walls throughout the body. Atheroscle-
rosis is thought to result from chronic inflammation 
and arterial wall injury in the peripheral or coronary 
vascular system. In response to endothelial injury and 
inflammation, oxidized lipids from low density lipo-
protein (LDL) particles accumulate in the endothelial 
part of the vessel wall. Angiotensin II may promote the 
oxidation of such particles. Then monocytes infiltrate 
arterial wall and differentiate into macrophages, which 
accumulate oxidized lipids to form foam cells. Once 
formed, foam cells stimulate macrophage proliferation 
and attraction of T-lymphocytes. T-lymphocytes, in 
turn, induce smooth muscle proliferation in the arterial 
walls and collagen accumulation. The net result of the 
process is the formation of a lipid-rich atherosclerotic 
lesion with a fibrous cap. Rupture of this lesion leads to 
acute vascular infarction; these ruptures and bleeding 
into the plaque are more frequent in diabetic patients. 
In addition to atheroma formation, there is strong evi-
dence for increased platelet adhesion, hypercoagulabil-
ity, impaired nitric oxide generation and increased free 
radical formation as well as altered calcium regulation 
in diabetic patients1-3.
Clinical Manifestations 
Diabetic polyneuropathy is primarily symmetric 
sensory neuropathy, initially affecting distal lower ex-
tremities. In 10%-18% of cases, patients have evidence 
of nerve damage at the time their diabetes is diag-
nosed, suggesting that even early impairment of glu-
cose handling, classified as prediabetes, is associated 
with neuropathy. Sensory loss ascends with progres-
sion of the disease and, when reaching approximately 
mid-calf, appears in the hands. This gradual evolution 
and typical “stocking-glove” sensory loss reflects pref-
erential damage according to axon length; the longest 
axons are affected first. Motor involvement with frank 
weakness occurs in the same pattern, but only later 
and in more severe cases4.
Diabetic neuropathy affects all peripheral nerves: 
pain fibers, motor neurons, autonomic nerves. It 
therefore necessarily can affect all organs and systems 
since all are innervated. Painful diabetic polyneuropa-
thy (PDN) may result from several varieties of dia-
betic neuropathy, the most common of which is distal 
sensory neuropathy. PDN can be further divided into 
acute and chronic PDN, or into stimulus independent 
and stimulus evoked PDN. Symptoms usually de-
velop gradually over years and vary depending on the 
nerve(s) affected5,6:
•  numbness and tingling of extremities 
•  dysesthesia (decreased or lost sensation to a body 
part) 
•  diarrhea 
•  erectile dysfunction 







•  speech impairment 
•  fasciculation (muscle contractions) 
•  anorgasmia 
•  burning or electric pain 
Different nerves are affected in different ways.
Sensorimotor polyneuropathy
Longer nerve fibers are affected to a greater degree 
than shorter ones because nerve conduction velocity is 
slowed in proportion to the nerve length. In this case, 
decreased sensation and loss of reflexes occurs first in 
the toes of each foot, and then extends upward. Usu-
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ally, this condition is described as glove-stocking dis-
tribution of numbness, sensory loss, dysesthesia and 
nighttime pain. The pain can feel like burning, prick-
ing sensation, achy or dull. Pins and needles sensation 
is common. Loss of proprioception, the sense of the 
limb in space, is affected early. These patients cannot 
feel when they are stepping on a foreign body, like a 
splinter, or when they are developing a callous from an 
ill-fitting shoe. Consequently, they are at risk of devel-
oping ulcers and infections on the feet and legs, which 
can lead to amputation. Similarly, these patients can 
get multiple fractures of the knee, ankle or foot, and 
develop a Charcot joint. The loss of motor function 
results in dorsiflexion, contractures of the toes, loss 
of the interosseous muscle function, and leads to con-
traction of the digits, so called hammer toes. These 
contractures occur not only in the foot but also in the 
hand, where the loss of the musculature makes the 
hand appear gaunt and skeletal. The loss of muscular 
function is progressive4-6.
Autonomic neuropathy
The autonomic nervous system is composed of 
nerves serving the heart, gastrointestinal system and 
genitourinary system. Autonomic neuropathy can af-
fect any of these organ systems. The most commonly 
recognized autonomic dysfunction in diabetics is or-
thostatic hypotension, or fainting when standing up. 
In case of diabetic autonomic neuropathy, it is due to 
the failure of the heart and arteries to appropriately 
adjust heart rate and vascular tone to keep blood con-
tinually and fully flowing to the brain. This symptom 
is usually accompanied by the loss of the usual change 
in heart rate seen with normal breathing. These two 
findings suggest autonomic neuropathy.
Gastrointestinal tract manifestations include de-
layed gastric emptying, gastroparesis, nausea, bloat-
ing, and diarrhea. Because many diabetics take oral 
medication for their diabetes, absorption of these 
medicines is greatly affected by the delayed gastric 
emptying. This can lead to hypoglycemia when an oral 
diabetic agent is taken before meal and does not get 
absorbed until hours or sometimes days later, when 
there is normal or low blood sugar already. Sluggish 
movement of the small intestine can cause bacterial 
overgrowth, made worse by the presence of hypergly-
cemia. This leads to bloating, gas and diarrhea.
Urinary symptoms include urinary frequency, ur-
gency, incontinence, and retention. Again, because of 
urine retention, urinary tract infections are frequent. 
Urinary retention can lead to bladder diverticula, 
stones, and reflux nephropathy4-6.
Cranial neuropathy
When cranial nerves are affected, oculomotor 
(3rd) neuropathies are most common. The oculomotor 
nerve controls all of the muscles that move the eye, 
with the exception of the lateral rectus and superior 
oblique muscles. It also serves to constrict the pupil 
and open the eyelid. The onset of diabetic third nerve 
palsy is usually abrupt, beginning with frontal or pe-
riorbital pain and then diplopia. All of the oculomo-
tor muscles innervated by the third nerve may be af-
fected, except for those that control pupil size. This 
is because pupillary function within CNIII is found 
on the periphery of the nerve (in terms of a cross sec-
tional view), which makes it less susceptible to isch-
emic damage (as it is closer to the vascular supply). 
The sixth nerve, the abducens nerve, which innervates 
the lateral rectus muscle of the eye (moves the eye 
laterally), is also commonly affected but the fourth 
nerve, the trochlear nerve (that innervates the supe-
rior oblique muscle, which moves the eye downward) 
involvement is unusual. Mononeuropathies of the 
thoracic or lumbar spinal nerves can occur and lead to 
painful syndromes that mimic myocardial infarction, 
cholecystitis or appendicitis. Diabetics have a higher 
incidence of entrapment neuropathies, such as carpal 
tunnel syndrome4-6.
Complications 
Diabetic neuropathy is frequently insidious in onset 
and can lead to the formation of foot ulcers and muscle 
and joint disease. Progressive sensory loss predisposes 
to ulcer formation. Foot ulcers are usually classified into 
two groups: acute ulcers secondary to dermal abrasion 
from poorly fitting shoes; and chronic plantar ulcers oc-
curring over weight-bearing areas. Chronic ulceration 
is probably multifactorial, due to a combination of dia-
betic neuropathy (with decreased pain sensation), auto-
nomic dysfunction and vascular insufficiency. 
Distal motor axonal loss results in atrophy of in-
trinsic foot muscles and an imbalance between the 
strength in toe extensors and flexors. This ultimately 
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leads to chronic metatarsal-phalangeal flexion (claw-
toe deformity), which shifts weight to the metatarsal 
heads. This weight shift results in the formation of 
calluses that can fissure, become infected and ulcer-
ate. There may also be other arthropathic changes in-
cluding collapse of the arch of the midfoot and bony 
prominences, leading to Charcot arthropathy, frag-
mentation and sclerosis of bone4-6.
Differential Diagnosis
It is important to appreciate that there are other 
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Table 1. The most frequent causes of polyneuropathy
there is any aspect of the history or clinical presen-
tation suggesting features atypical of diabetic neu-
ropathy (e.g., signs of a systemic disease: vascular, 
metabolic, toxic, carcinomatous, infectious, immune, 
genetic, etc.) (Table 1)7-9. 
Diagnostic Criteria
The earliest signs of diabetic neuropathy prob-
ably reflect the gradual loss of integrity of both large 
myelinated and small myelinated and unmyelinated 
nerve fibers. The loss of vibratory sensation and altered 
proprioception reflect large-fiber loss. Impairment of 
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pain, light touch and temperature is secondary to the 
loss of small fibers. Decreased or absent ankle reflexes 
occur early in the disease, while a more widespread 
loss of reflexes and motor weakness are late findings. 
Diagnosis of diabetic neuropathy should be estab-
lished according to clinical manifestations of the dis-
ease, laboratory findings (altered glucose metabolism) 
and results of electrophysiological examinations (elec-
tromyoneurography)8.
Michigan Neuropathy Screening Score is a simple 
screening test to diagnose diabetic neuropathy in out-
patient clinics. On this simple examination, the fol-
lowing questions are addressed:
•  Do the feet show dry skin, callus, fissure, infection 
or deformities? The presence of any of these indi-
cators of neuropathy is scored as one point and an 
additional point is added if an ulcer is present. 
•  What is the vibration sense on the dorsum of the 
great toes? reduced (0.5 points) or absent (1 po-
int). 
•  What is the Achilles tendon reflex? absent (1 po-
int) or present with reinforcement (0.5 points). 
A score greater than 2 indicates neuropathy with 
both high specificity (95 percent) and sensitivity (80 
percent). The Michigan Neuropathy Screening Test 
can be administered by any health care professional 
involved in the treatment of diabetic patients4,8.
Tuning fork test as a simple test using a 128 Hz 
tuning fork to examine vibration perception can be 
used to screen for diabetic polyneuropathy. A 128 Hz 
tuning fork is placed on the interphalangeal joint of 
the right hallux. 
•  The score is 2 points, if the patient feels no vibration. 
When the patient feels vibration at the hallux, the 
still vibrating tuning fork is immediately placed at the 
dorsal wrist, and the patient is asked to compare the 




rence at the wrist. 
Normal score is 0 points, mild to moderate deficit 
is 1, and severe deficit is 2.
This tuning fork test has widespread utility in 
clinical practice because it is simple, brief, valid and 
reliable4,8.
United Kingdom screening test. In the United 
Kingdom, investigators have developed a two-part 
diagnostic test consisting of a simple symptom score 
and physical examination:
•  What is the sensation felt? burning, numbness, or 
tingling in the feet (2 points); fatigue, cramping, or 
aching (1 point). Maximum is 2 points. 
•  What is the location of symptoms? feet (2 points); 
calves (1 point); elsewhere (no points). Maximum 
is 2 points. 
•  Have the symptoms ever awakened you at night? 
yes (1 point). 
•  What is the timing of symptoms? worse at night 
(2 points); present day and night (1 point); present 
only during the day (no points). Maximum is 2 po-
ints. 
•  How  are  symptoms  relieved?  walking  around  (2 
points); standing (1 point); sitting or lying, or no 
relief (no points). Maximum is 2 points. 





A similar quantitative score can be made for physical 
findings:
•  What is the Achilles tendon reflex? absent (2 po-
ints for each foot); present with reinforcement (1 
point for each foot). 
•  What is vibration sense? absent or reduced (1 point 
for each foot). 
•  What is pin prick sensation? absent or reduced (1 
point for each foot). 
•  What  is  temperature  sensation?  reduced  (1 point 
for each foot). 
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Peripheral neuropathy is considered to be present 
if there are moderate or severe signs (≥6 points), even 
in the absence of symptoms, or if there are at least 
mild signs (≥3 points) in the presence of moderate 
symptoms (≥5 points). A neurologic sign score of 8 or 
more indicates that the patient’s feet are at a high risk 
of ulceration4,8.
Pain quality and intensity can be estimated with 
the Neuropathic Pain Scale, the Neuropathic Pain 
Questionnaire, and other scales. There are several dif-
ferent aspects of pain we are interested to measure: 
pain intensity (0-10), pain sharpness (0-10), heat (0-
10) or cold (0-10), dullness (0-10), overall unpleasant-
ness (0-10), how sensitive the skin is to light touch 
(0-10), how itchy pain is (0-10), time quality of pain 
(background vs. flare-up, all the time vs. sometimes), 
and surface pain (0-10) vs. deep pain (0-10). Many 
people are able to tell the difference between many 
aspects of their pain: for example, how much it hurts 
and how unpleasant or annoying it is. Although often 
the intensity of pain has a strong influence on how 
unpleasant the experience of pain is, some people are 
able to experience more pain than others before they 
feel very bad about it. There are scales for measuring 
different aspects of pain. For one patient, a pain might 
feel extremely hot, but not at all dull, while another 
patient may not experience any heat, but feels his/her 
pain is very dull. We expect from the patient to rate 
very high on some of the scales and very low on oth-
ers. 
An assessment of global function, sleep, psycho-
logical comorbidity, and other issues should be under-
taken to determine the effect of diabetic neuropathy on 
the patient’s quality of life, using a neuropathy-specif-
ic tool such as the Norfolk Quality of Life for Diabetic 
Neuropathy (QOL-DN) instrument. It is composed of 
46 items. Items 1-7 are nerve fiber-related symptoms 
(numbness, tingling/pins and needles, electric shocks, 
superficial peripheral pain, deep pain, weakness, and 
other symptoms). Items 8-11 inquire about duration 
of symptoms, symptoms at night, and current medi-
cations. Items 12-15 cover neuropathy diagnosis and 
related complications. Questions 8-15 are not includ-
ed in the statistical analysis of the scales. With items 
16-37, subjects respond to questions about the degree 
of physical problems that interfere with their activities 
of daily living. These items are scored on a five-point 
Likert scale (0, no problem to 4, severe problem). 
Items 38-46 are generic questions about health and 
not specific to neuropathy. They are also measured on 
a five-point Likert scale4,8.
Treatment
Treatment of DPN rests on a two-pronged ap-
proach: modification of the underlying disease and 
control of pain symptoms. Disease modification in-
cludes tight glycemic control, which in one study re-
duced the risk of development of clinical diabetic neu-
ropathy in patients with insulin-dependent diabetes 
by as much as 62%. The maintenance of ideal body 
weight and normal lipid levels is also fundamental to 
the prevention of diabetic neuropathy. Recognition of 
the clinical symptomatology produced by the various 
pathogenic mechanisms described above will ulti-
mately provide a logical basis for pain treatment se-
lection. Intensive glucose control (HbA1c ≤7 mmol/L) 
with diabetic diet, peroral antidiabetic agents or in-
sulin, particularly when instituted early in DM, delay 
or prevent clinically manifest DPN. There is still no 
cure for DPN, as pharmacotherapy can only treat the 
symptoms of DPN10,12.
The goals of DPN pharmacotherapy should be:
•  Reduction of pain for maximum relief commensu-
rate with acceptable side effects.
•  Restoration/improvement  in  functional measures 
and quality of life.
Patients with painful DPN may share some co-
morbidities (anxiety, depression, sleep disorders) with 
those having chronic pain, requiring treatment in re-
ferral pain center. The main pharmacological agents, 
their mechanisms of action, recommended doses, side 
effects and level of evidence are shown in Tables 2, 3 
and 4.     
Pharmacotherapy
Antidepressants
Tricyclic antidepressants (TCAs) are accepted 
choices in neuropathic conditions and a meta-analysis 
of randomized clinical trials indicated their efficacy 
in treating painful diabetic (DPN) and nondiabetic 
polyneuropathy.
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Drug Recommended dosage Main characteristics
Tricyclic antidepressants (TCAs)
Amitriptyline
Initially 10-25 mg at bed time; titrate in 
increments 10-25 mg based on effectiveness/
tolerability to 100-150 mg/day
Balanced monoamine reuptake inhibition• 
Oldest, best known, commonly used as a golden standard for • 
TCA
Contraindicated MAOIs, in cardiovascular disease• 
Avoid SNRIs and tramadol• 
Nortriptyline
Initially 10 mg at bed time; titrate in 
increments 10-25 mg based on effectiveness/
tolerability to 50-100 mg/day
Active metabolite of amitriptyline• 
Avoid SNRIs and tramadol• 
Imipramine
Initially 10 mg at bed time; titrate 
in increments 10-25 mg based on 
effectiveness/tolerability to 50-100 mg/day
Balanced monoamine reuptake inhibition• 
Contraindicated MAOIs, in cardiovascular disease• 
Avoid SNRIs and tramadol• 
Desipramine
Initially 10 mg at bed time; titrate in 
increments 10-25 mg based on effectiveness/
tolerability to 50-100 mg/day
Predominantly norepinephrine reuptake inhibition• 
active metabolite of imipramine• 
Contraindicated MAOIs, in cardiovascular disease• 
Avoid SNRIs and tramadol• 
Voltage channel blockers
Carbamazepine Initially 200 mg/day; titrate in increments of 100 mg q 12 h to max 1200 mg/day
Voltage-gated sodium-channel block• 
Contraindicated in pts with bone marrow depression and acute • 
porphyria
Caution in hepatic dysfunction• 
Monitor patients for leukopenia• 
Avoid MAOIs, TCAs, •  α2δ CCMs
Oxcarbazepine Initially 300 mg/day; titrate in increments of 100 mg q 12 h to max 2400 mg/day
Voltage-gated sodium- and calcium-channel block• 
Monitor patients total blood count• 
Lower dosage in pts with renal impairment (CrCl <30 mL/• 
min)
Avoid MAOIs, TCAs, •  α2δ CCMs
Valproic acid Starting dose is 125-250 mg q 12 hours, max 1200 mg/day
Contraindicated in pregnancy due to congenital abnormalities• 
Hyperandrogenism due to elevated testosterone levels and • 
ovarian cysts
Caution in hepatic dysfunction• 
Monitor patient total blood count• 
Lamotrigine
Initially 25 mg first week, then titrate in 
increments 25 mg/day every week to max 
400 mg/day
Presynaptic voltage-gated sodium-channel inhibition and thus • 
reduced release of presynaptic transmitters
Antidepressant effect appropriate if comorbid depression and • 
intolerant/unresponsive to duloxetine, TCAs or venlafaxine
Discontinue if rash develops, unless rash clearly not drug • 
related
Abrupt discontinuation may precipitate seizures • 
Topiramate
Initially 25-50 mg, then titrate in 
increments 25 mg/day every week to max 
800 mg/day
Voltage-gated sodium-channel blockade inhibition of • 
glutamate release by an action on AMPA/kainite receptors
Abrupt discontinuation may precipitate seizures• 
Alpha-delta 2 calcium channel modulators/anticonvulsants (α2δ CCMs)
Gabapentin
Initially 300 mg at bed time – 1&2 days, bid 
days 3&4, tid days 5&6; continue titration 
based on effectiveness/tolerability up to 
max 1800 mg/day; reduce dosage if renal 
insufficiency
Binding to the •  α2δ subunit of voltage- dependent calcium 
channels with reduced release of presynaptic transmitters
Avoid other •  α2δ CCMs
Abrupt discontinuation may precipitate seizures• 
Table 2. Diabetic neuropathy – mechanisms of action, recommended doses and side effects of specific drugs
296 Acta Clin Croat,  Vol. 50,   No. 2,  2011
Vanja Bašić-Kes et al. Recommendations for diabetic polyneuropathy treatment 
Pregabalin
Start with 50 mg bid-tid if CrCl ≥60mL/
min (if lower, adjust starting dose 
downward); titrate in increments based on 
effectiveness/tolerability up to max 300 mg/
day 
Binding to the •  α2δ subunit of voltage- dependent calcium 
channels with reduced release of presynaptic transmitters
Avoid other •  α2δ CCMs
If therapy ended, withdraw gradually over min 1 week• 
Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Duloxetine
Initially 60 mg/day (if renal impairment, 
lower starting dose and gradually increase); 
to blunt potential nausea, initiate therapy at 
30 mg/day taken with food for first week
Serotonin-norepinephrine reuptake inhibition• 
Contraindicated if concomitant MAOIs, uncontrolled narrow-• 
angle glaucoma
Not recommended in end-stage renal disease, severe renal • 
impairment (CrCl <30 mL/min), hepatic insufficiency, active 
alcoholism
Avoid other SNRIs, TCAs, tramadol• 
Venlafaxine
37.5 initially once daily with food; titrate 
in increments based on effectiveness/
tolerability to max 225 mg daily (lower 
dosage if hepatic or renal impairment)
Serotonin-norepinephrine reuptake inhibition• 
Use if non-responsive to or intolerant of first line agents• 
Contraindicated if concomitant MAOIs, uncontrolled narrow-• 
angle glaucoma
Avoid SNRIs, TCAs, tramadol• 
If discontinuing therapy, taper off gradually• 
µ-Opioid-receptor agonists
Oxycodone
10-60 mg q 12 h, based on effectiveness/
tolerability; adjust starting dose downward 
if hepatic or renal impairment (CrCl <60 
mL/min)
μ-Opioid-receptor agonist• 
Tablets should be swallowed whole, not crushed or chewed• 
µ-Opioid-receptor agonist and monoamine reuptake inhibitor
Tramadol
25 mg/day initially; titrate in increments of 
25 mg/day (as separate doses) q 3 day to 100 
mg/day (25 mg qid); thereafter in increments 
of 50 mg/day (as tolerated) q 3 day to 200 
mg/day (50 mg qid); after titration, 50-100 
mg q 4-6 h to max  400 mg/day; in cirrhosis, 
50 mg q 12 h; if CrCl <30 mL/min, dosing 
interval q 12 h to max 200 mg/day  
μ-Opioid-receptor agonist and monoamine reuptake inhibitor• 
Most common side effects are constipation, sedation, nausea, • 
dizziness and vomiting
Avoid other SNRIs, MAOIs, TCAs• 
Topical agents (adjunctive therapy)
Capsaicin Topical cream – apply 4 times daily on painful areas
Depolarizes nervous membrane via vanilloid receptor type 1, • 
initially stimulates, then blocks skin nerve fibers
Lidocaine 5% lidocaine patches – apply on painful areas Block of peripheral sodium channels and thus of ectopic • discharges
Nitrates
Glyceryl trinitrate patches – apply on painful 
areas
Isosorbide dinitrate spray – apply on painful 
areas
Impaired neuronal NO generation induces hyperalgesia, topical • 
nitrates regulate NO metabolism
Antihyperalgesic effects of tricyclic antidepres-
sants may be related to enhancement of noradrenergic 
descending inhibitory pathways and partial sodium 
channel blockade, mechanisms that are independent 
of their antidepressant effects.
Starting doses of TCAs should be low and dosage 
should be titrated slowly until pain is adequately con-
trolled or side effects limit continued titration.
Some of the third-generation antidepressants, es-
pecially venlafaxine and duloxetine, have been shown 
to have comparable efficacy to the TCAs, but with a 
better side effect profile.
Duloxetine is a selective serotonin and norepi-
nephrine reuptake inhibitor (SSNRI) that inhibits 
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the reuptake of both serotonin and norepinephrine. 
It has demonstrated significantly greater pain relief 
compared with placebo in several randomized clinical 
trials (RCTs) in patients with DPN. The optimal dos-
age of duloxetine is 60 mg/day.
Venlafaxine is an SSNRI that inhibits serotonin 
reuptake at lower dosages and both serotonin and 
norepinephrine reuptake at higher dosages. The effi-
cacy dosage of venaflaxine is 150-225 mg/day. A 2- to 
4-week period is often required to titrate to an effec-
tive dosage18-20.
Side effects of TCAs
The most common side effects of TCAs are dry 
mouth, constipation, sweating, dizziness, disturbed 
vision, drowsiness, palpitation, orthostatic hypoten-
sion, sedation and urinary hesitation. More selective 
TCAs such as nortriptyline are better tolerated than 
the non-selective ones, with less anticholinergic ef-
fects and sedation. A suspected association between 
TCA treatment and sudden cardiac death has raised 
concern; a recent epidemiological study found a slight 
increase in sudden cardiac death with TCA doses 
greater than 100 mg/day. Therefore, caution is advised 
for older patients, particularly those with cardiovascu-
lar risk factors18-20.
The SSNRIs (duloxetine, venlafaxine) are safer to 
use than TCAs and are a better option in patients with 
cardiac disease. The relative risk of withdrawal due to 
side effects is low and there is no need for drug level 
monitoring. The most frequently observed adverse 
events with duloxetine are nausea, vomiting, consti-
pation, somnolence, dry mouth, increased sweating, 
loss of appetite and weakness. Although immediate 
release venlafaxine is associated with adverse central 
nervous system and somatic symptoms such as agita-
tion, diarrhea, increased liver enzymes, hypertension 
and hyponatremia, the extended release formulation 
seems to be far more tolerable, the main side effects 
being gastrointestinal disturbances18-20.
Anticonvulsants
The anticonvulsant compounds are some of the 
best-studied drugs for neuropathic pain and there is 
substantial evidence for their efficacy based on meta-
analyses and randomized clinical trials.
Multiple RCTs have shown the efficacy of many of 
these drugs in a large variety of types of neuropathic 
Table 3. Classification of evidence for main categories of diabetic neuropathy drug treatment
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pain. Unfortunately, complete relief of any form of 
neuropathic pain is only rarely achieved with the use 
of antiepileptic drugs. Usually, pain reduction by 50% 
is achieved in only one-half of treated patients21.
Perhaps the most extensively studied agent is 
pregabalin, which has shown, in a large number of 
multicenter RCTs, clear efficacy in reducing pain and 
improving sleep in patients with postherpetic neural-
gia and diabetic polyneuropathy. The effective dosage 
is 300-600 mg/day, administered in two to three di-
vided doses. Improvement can be seen within days. 
Pregabalin is believed to exert its analgesic effect by 
binding to the α2 delta subunit of voltage-gated cal-
cium channels on primary afferent nerves, and reduc-
ing the release of neurotransmitters from their central 
terminals. Multicenter RCTs have shown the efficacy 
of gabapentin at dosage of 900-3600 mg/day in the 
treatment of postherpetic neuralgia and diabetic poly-
neuropthy. Gabapentin is a GABA receptor agonist. 
The ability of the drug to block L-type voltage-de-
pendent Ca2+ channels is the probable reason for its 
antiepileptic and analgesic properties22-27.
There is also evidence for the efficacy of topiramate, 
lamotrigine, carbamazepine and oxcarbamazepine in 
the treatment of different DPN conditions. Carbam-
azepine and perhaps oxcarbamazepine are used as 
first-line therapy for trigeminal neuralgia28,29.
Side effects of anticonvulsants
Carbamazepine (CBZ) entails frequent adverse 
events, which include sedation, dizziness, and gait ab-
normalities. Liver enzymes, blood cells, platelets and 
sodium levels must be monitored for at least 1 year due 
to the possible risk of hepatitis-anaplastic effects or 
hyponatremia. Induction of microsomal enzyme sys-
tems may influence the metabolism of several drugs. 
In contrast to CBZ, oxcarbazepine (OXC) does not 
entail enzymatic induction and there is little risk of 
crossed cutaneous allergy37,38,40. In the first months of 
treatment, sodium levels must be monitored because 
OXC, like CBZ, induces hyponatremia, particularly 
in the elderly (6% in a cohort of 54 patients). As re-
gards other side effects, although better tolerance has 
been claimed with OXC compared with CBZ, this 
notion lacks consistent evidence from class I trials. 
In a recent trial in painful DPN, 27.5% of the OXC 
group discontinued treatment due to central or gas-
trointestinal side effects versus 8% on placebo28,29.
The most common side effects of gabapentin 
(GBP) and pregabalin include dizziness, somnolence, 
peripheral edema, and dry mouth, with a similar fre-
quency for both drugs. Whilst GBP is widely accepted 
as highly tolerable even at high dosages (>2400 mg), 
the reports on pregabalin change remarkably with 
the daily dose: with 150 to 300 mg there is almost 
no difference from placebo, whilst the withdrawal rate 
reaches 20% with 600 mg22-27.
Lamotrigine is generally well tolerated. Side ef-
fects include dizziness, nausea, headache and fatigue. 
However, it may induce potentially severe allergic skin 
reactions. Lamotrigine should not be used in combi-
nation with valproate30-32. 
Opioids
Opioids may be useful, especially in acute stage, 
but their use for chronic pain management remains 
somewhat controversial. A meta-analysis of interme-
diate term studies with opioids (up to eight weeks) 
showed a significant reduction in pain scale measure-
ment for patients with DPN, comparable to results 
with maximal dose gabapentine.
Patients are candidates for opioid therapy after all 
other appropriate therapies have failed. 
Opioids exert their analgesic effect through at least 
four groups of receptors. The distribution of these re-
ceptors throughout the body, along with their tissue 
densities within numerous organ systems, account for 
the global and varied effects of these drugs. 
Opioids are available in a variety of preparations. 
In addition to common, PO, IM and IV route of ad-
ministration, they may be given transdermally (fenta-
nyl as buprenorphine patch), transmucosally (fentanyl 
oral), and intraspinally33-36.
Side effects
The most common side effects of opioids are con-
stipation, sedation, nausea, dizziness and vomiting. 
The risk of cognitive impairment has been reported to 
be negligible, although morphine may impair atten-
tion at very high dosages. Tramadol has been reported 
to induce dizziness, dry mouth, nausea, constipation 
and somnolence with significantly more dropouts 
compared with placebo. There is an increased risk of 
seizures in patients with a history of epilepsy or re-
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ceiving drugs that may reduce the seizure threshold. 
Serotonergic syndrome (various combinations of myo-
clonus, rigidity, hyperreflexia, shivering, confusion, 
agitation, restlessness, coma, autonomic instability, 
fever, nausea, diarrhea, flushing, and rarely rhab-
domyolysis and death) may occur if tramadol is used 
as an add-on treatment to other serotonergic medica-
tions (particularly selective serotonin reuptake inhibi-
tors, SSRIs)33-36. 
Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are effective in patients with musculoskeletal or joint 
abnormalities secondary to long-standing neuropathy; 
joint deformities may actually be the primary source 
of pain. Both ibuprofen (600 mg four times daily) and 
sulindac (200 mg twice daily) can lead to substantial 
pain relief in patients with diabetic neuropathy.
There is a theoretical concern that NSAIDs may 
impair nerve circulation and worsen nerve injury due 
to inhibition of prostacyclin synthesis. Cautious use of 
this class of drugs is warranted until this possibility is 
fully evaluated12.
Others
Levodopa has been evaluated as the possible 
treatment in some cases of painful diabetic neuropa-
thy (double-blind placebo-controlled study, 100 mg 
levodopa plus 25 mg benserazide to be taken three 
times per day for 28 days). The results seemed promis-
ing and levodopa may be a choice for pain control in 
neuropathy for which we do not have many alternative 
treatments37.
Some clinical studies have shown efficacy of dex-
tromethorphan (400 mg/day) and memantine (55 or 
35 mg/day) in the treatment of DPN. The mean reduc-
tion in pain intensity was 6% with dextromethorphan 
and 2% with memantine. In subjects who responded 
to dextromethorphan, there was a significant dose-
response effect on pain intensity (P=0.035). Selective 
approaches to pain-relevant N-methyl-d-aspartate re-
ceptors are warranted38,39.
Diabetic autonomic neuropathy is extremely dif-
ficult to treat, and the risks and adverse effects fre-
quently outweigh the benefits of most pharmaco-
logical therapies. The symptoms may be ameliorated 
with fludrocortisone, clonidine, midodrine, dihydro-
ergotamine or caffeine, octreotide, ACE inhibitors, 
and β-blockers. Gastroparesis may be improved with 
metoclopramide or erythromycin, but glycemic con-
trol is perhaps the best long-term treatment. Erectile 
dysfunction may respond to phosphodiesterase in-
hibitors, vacuum-constriction devices, and intracaver-
nosal injections40.
Nonspecific pharmacological treatment options 
Alpha-lipoic acid 
One of the mechanisms implicated in the patho-
genesis of diabetic neuropathy is increased oxidative 
stress. As a result, antioxidants have been studied for 
their potential to diminish oxidative stress, improve 
the underlying pathophysiology of neuropathy, and 
reduce pain. Based on data of randomized clinical tri-
als, we suggest treatment with oral α-lipoic acid 600 
mg once daily for patients with symptomatic painful 
diabetic polyneuropathy1-3,40,41.
Acetyl-L-carnitine 
Acetyl-L-carnitine (ALC), the acetylated ester 
of the amino acid L-carnitine, has been evaluated in 
patients with diabetic peripheral neuropathy. Accord-
ing to data from two randomized controlled trials of 
identical design, an intention to treat analysis of 1257 
DPN patients showed ALC 1000 mg (but not 500 
mg) three times daily compared with placebo to be as-
sociated with significant improvement in pain scores 
in one of the studies and in the combined cohort. The 
benefit of ALC requires confirmation, particularly 
since significant improvement was not seen in both 
trials or at the lower dose of ALC1,40,41.
Protein kinase C inhibition
Elevated protein kinase C activity is thought to 
play a substantial role in the etiology of diabetic micro-
vascular complications. Studies have been conducted 
using a protein kinase C-β inhibitor (LY333531). A 
preliminary study suggested the possibility of this 
agent to improve positive symptoms of allodynia and 
prickling pain. Large phase III multicenter clinical 
trials are in progress1,40,41.
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Aldose reductase inhibitors 
In addition to lowering blood glucose concentra-
tions, another potential approach is to minimize the 
toxicity of hyperglycemia. To the degree that sorbitol 
accumulation might play a role in diabetic neuropa-
thy, the use of an aldose reductase inhibitor to prevent 
sorbitol formation might be beneficial. In the studies 
reported thus far, there has usually been no improve-
ment in pain, an inconsistent effect on paresthesias, 
and an improvement in nerve conduction in some but 
not all nerves1,40,41. 
Angiotensin converting enzyme inhibitors 
Angiotensin converting enzyme (ACE) inhibitors 
play a major role in the treatment of hypertension and 
in the prevention of progression of nephropathy in pa-
tients with diabetes. ACE inhibitors presumably act 
by inhibiting the production of angiotensin II, there-
by lowering systemic and intraglomerular pressures. 
By mechanisms that are less clear, these drugs may 
also be beneficial in diabetic retinopathy and neuropa-
thy1,40,41. 
Surgical decompression 
Surgical decompression of multiple peripheral 
nerves (called the Dellon procedure) is an alternative, 
controversial method for treating DPN. The purport-
ed rationale for surgical decompression is based on the 
notion that the metabolic stress of diabetes renders 
peripheral nerves susceptible to compressive injury at 
sites of potential nerve entrapment, and that compres-
sive injury of multiple peripheral nerves is what leads 
to symptoms in most patients.
While there is some experimental evidence that 
favors this hypothesis, other evidence to the contrary 
suggests that diabetes may partially prevent axonal in-
jury by the development of resistance to axonal degen-
eration after nerve compression. In addition, there are 
no appropriately designed trials to support the use of 
surgical decompression of multiple peripheral nerves 
as a treatment for symptomatic DPN. Therefore, this 
treatment is not recommended1-3,40,41.
Nonpharmacological treatment
Acupuncture
Acupuncture is a complementary and alternative 
medical modality. Since 1998, a considerable num-
ber of acupuncture studies have been reported. It has 
been integrated into palliative care medicine. Most of 
controlled clinical trials (23/27) have shown results 
favoring acupuncture use for the conditions such as 
nausea, vomiting and pain. They also have shown that 
acupuncture is safe and clinically cost-effective for 
management of common symptoms in palliative care 
and hospice patients. There is the risk of skin irritation 
or allergic reaction from application of needles to the 
skin, but these problems are relatively rare and easily 
managed by shifting the needle position. There is not 
yet enough evidence-based treatment recommenda-
tions (level C)20-22,66.
Transcutaneous electrical nerve stimulation
High frequency (80-110 Hz) and low frequency 
(2-10 Hz) transcutaneous electrical nerve stimulation 
(TENS) differ in their ability to relieve pain and in the 
central nervous system alterations they produce. High 
frequency TENS relieves secondary allodinya via mus-
carinic and μ opioid receptor dependent mechanisms, 
while low frequency TENS relieves secondary allo-
dynia via serotonin, muscarinic and δ opioid receptor-
dependent mechanism. In addition, recent evidence 
indicates that high and low frequency TENS may pro-
duce distinct cortical activation patterns when produc-
ing analgesia. There are not yet enough evidence-based 
treatment recommendations (level C). TENS produces 
none of the side effects associated with drug therapy. 
There is the risk of skin irritation or allergic reaction 
from the application of electrodes to the skin, but these 
problems are relatively rare and easily managed by 
shifting the electrode position1-3,40,41.
Others
Laser therapy, mechanotherapy (massage), elec-
trotherapy (galvanization, iontophoresis), ultrasound 
therapy, thermotherapy (cold and warm), hydro/bal-
neotherapy and behavioral therapy (relaxation, bio-
feedback) have been tried. There is still no evidence-
based treatment recommendations due to the lack of 
controlled studies in this field (level C)1,40,41.
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Sažetak
PREPORUKE ZA LIJEČENJE DIJABETIČNE POLINEUROPATIJE
V. Bašić-Kes, I. Zavoreo, K. Rotim, N. Bornstein, T. Rundek i V. Demarin
Dijabetes spada u skupinu kroničnih bolesti koja zahtijeva stalno medicinsko praćenje te izobrazbu bolesnika o mje-
rama prevencije kako bi se spriječio razvoj komplikacija. U razvijenim zemljama dijabetes je vodeći uzrok neuropatija, a 
neuropatije su jedna od najčešćih komplikacija dijabetesa, te najveći uzrok pobola i smrtnosti u bolesnika s dijabetesom. U 
trenu kada se postavi dijagnoza dijabetesa 10%-18% bolesnika već ima oštećenje živaca, što govori u prilog činjenici da čak 
i početni poremećaji metabolizma glukoze pod zajedničkim nazivnikom preddijabetes mogu uzrokovati neuropatiju. Kod 
postavljanja dijagnoze dijabetične neuropatije treba isključiti i druge uzroke neuropatija ako se radi o atipičnoj kliničkoj 
slici ili nekim drugim istodobnim bolestima. Dijagnoza se postavlja u skladu sa smjernicama, a na osnovi kliničke slike, 
laboratorijskih nalaza (poremećaj metabolizma glukoze) i rezultata elektrofizioloških pretraga. Liječenje bolne dijabetične 
polineuropatije temelji se na dva dugoročna načela, a to su liječenje osnovne bolesti (dijabetes) i liječenje bolne sastavnice. 
Osnovni ciljevi liječenja bolne sastavnice su smanjenje boli uz prihvatljive rizike i nuspojave uzimanja specifičnih lijekova 
te poboljšanje kvalitete života.    
Ključne riječi: Dijabetična neuropatija – terapija; Bol – terapija; Bol – analiza; Smjernica
